Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation

May 1, 2024

https://www.globenewswire.com/news-release/2024/05/01/2873265/0/en/Altamira-Therapeutics-Announces-Filing-of-Provisional-Patent-Application-for-OligoPhore-Nanoparticles-with-siRNA-Targeting-p65-Protein-in-Treatment-of-Cancer-and-Inflammation.html

Hamilton, Bermuda, May 01, 2024 (GLOBE NEWSWIRE) —

HAMILTON, BERMUDA / May 1, 2024 / Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced that it has filed a provisional patent application with the United States Patent Office (USPTO) which covers nanoparticles comprising the Company’s OligoPhore™ platform and siRNA targeting the p65 protein, a component of the NF-κB transcription factor.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.